E3 ubiquitin-protein ligase RNF31 inhibitor (Flindr Therapeutics)

N/A

Report date: 2025/06/11 10:53:49
NME

Base Information

Drug NameE3 ubiquitin-protein ligase RNF31 inhibitor (Flindr Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionE3 ubiquitin-protein ligase RNF31 inhibitors
TargetsE3 ubiquitin-protein ligase RNF31
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStichting Oncode Institute
China Registration ClassN/A

Develop Information

Active CompaniesFlindr Therapeutics BV
Inactive CompaniesStichting Oncode InstituteThe Netherlands Cancer Institute
Active IndicationsSolid tumoursHematologic NeoplasmsOvarian Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A